This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Pfizer Q1 Profit Falls 19 Pct On Generic Lipitor

LINDA A. JOHNSON

Pfizer Inc. said Tuesday that its first-quarter profit fell 19 percent, mainly because new generic competition to its blockbuster cholesterol pill Lipitor cut U.S. sales by 15 percent as the drugmaker offered big rebates and discounts to keep patients on its brand.

The world's biggest drugmaker beat Wall Street's profit expectations but narrowly missed its sales forecast. It lowered its adjusted profit forecast for 2012 by 6 cents, to $2.14 to $2.24 per share. Analysts had predicted $2.26 per share. Including one-time items, it expects earnings per share of $1.23 to $1.38.

New York-based Pfizer said the change was due to its recent decision to sell its infant-nutirition business to Swiss food and drink giant Nestle SA for $11.85 billion. The steep drop in Lipitor revenue was factored into its previous forecasts.

The maker of Viagra said net income was $1.79 billion, or 24 cents per share, down from $2.22 billion, or 28 cents a share, a year earlier.

Excluding one-time items, Pfizer would have made $4.43 billion, or 58 cents per share. Analysts were expected 56 cents a share.

Revenue totaled $15.4 billion, down 7 percent from $16.5 billion a year ago. Analysts were expecting $15.46 billion.

Sales in the U.S., where Pfizer's patent expired on Nov. 30 for Lipitor, the top-selling drug in history, fell to $5.95 billion, from $7.02 billion. International sales edged up 1 percent, to $9.45 billion.

Lipitor sales fell 42 percent, to $1.4 billion from $2.39 billion.

"I am pleased with out first-quarter 2012 financial performance, which was driven by growth in certain brands including Celebrex, Enbrel and Lyrica, growth in key geographies such as China" and cost-cutting, CEO Ian Read said in a statement.

Revenue from prescription medicines fell 8 percent to $13.07 billion, as sales declined in the oncology, primary care and specialty care businesses.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,055.29 -15.93 -0.09%
S&P 500 1,975.65 -2.15 -0.11%
NASDAQ 4,496.5090 -9.3430 -0.21%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs